Key Highlights
- A £9.15m placing of 9.15bn shares at 0.1p represents 68.1% of the enlarged company, which now has 13,440,910,967 shares.
- The circular stated cash was expected to be exhausted by early September 2026 without the placing.
- PSE orders reached 1,788 in the half, up 126% year on year and 66% above the second half of FY25.
- Interim Revenue rose 17% to £0.69m while the operating loss narrowed 20% to £4.68m.
Oxford BioDynamics Plc (LSE:OBD) has spent August 2026 pulling itself back from the edge. On 10 August the 3D-genomics diagnostics group said its cash would run out by early September without a £9.15m placing at just 0.1p a share, a deal handing new investors 68.1% of the enlarged company. Shareholders approved it on 26 August and the shares were admitted to AIM the next morning.
The rescue arrived alongside a new narrative: a commercial chief executive hired from Oxford Nanopore, a first paying customer for the EpiSwitch Orion platform, a UAE partner for the PSE prostate test and PSE volumes more than doubling year on year. The question is whether that operating momentum can outrun a Balance Sheet that has needed three share placings in 19 months.
£9.15m placing at 0.1p: survival secured, dilution severe
On 10 August 2026 Oxford BioDynamics announced a £9.15m gross (about £8.4m net) placing of 9.15bn new ordinary shares at 0.1p, a 9.1% discount to the 0.11p closing price on 7 August. The enlarged share count is 13,440,910,967, so the placing shares represent 68.1% of the company.
The circular was unusually frank. Absent the placing, "existing cash resources are expected to be exhausted by early September 2026". With net Assets below half of called-up share capital, the board also disclosed a "serious loss of capital" under section 656 of the Companies Act 2006, and said that had the resolutions failed it would have pursued alternative funding, an asset sale or an orderly wind-up. The placing was not underwritten.
Insiders backed the deal. Chief executive Richard Compton subscribed for 300m shares (2.2% of the enlarged capital), chairman Iain Ross for 100m, and directors Paul Stockdale and Dr Alexandre Akoulitchev for 25m and 30m respectively. Non-executive Martin Diggle's Vulpes Investment Management took 500m shares to reach 8.3%, and Pentwater Capital Management 700m to hold 8.9%.
Proceeds are earmarked for Orion pilot projects, PSE growth including an NHS pilot, a partner-funded CiRT evidence programme and a colorectal cancer study. The board expects the money to last at least 12 months, but cautioned that this depends on "the timing and scale of future revenues, including from transactions that have not yet been agreed".
"This Placing will provide the Working Capital to execute that strategy, building on the continued growth in PSE test sales and last month's first commercial agreement for EpiSwitch Orion," said Compton, who formally joined the board on 27 August 2026.
What Oxford BioDynamics does
Oxford BioDynamics has built its EpiSwitch platform around 3D genomics: reading how chromosomes fold and interact rather than just the linear DNA sequence, a structural layer the company argues contains biomarkers conventional sequencing misses. It has run more than 40 collaborations with groups including Pfizer, Genentech, Roche and the Mayo Clinic.
Revenue comes mainly from two blood tests processed in laboratories in Oxford and Frederick, Maryland. EpiSwitch PSE is a prostate cancer test used alongside PSA screening; EpiSwitch CiRT predicts response to checkpoint-inhibitor immunotherapy. A ME/CFS test is in validation, targeting availability by the end of 2026.
The newest product is EpiSwitch Orion, launched in March 2026: a cloud-based platform that applies the company's 1.5bn-datapoint 3D-genomics knowledgebase to standard sequencing data to find disease-associated variants in non-coding regions. Compton has reorganised the Business around four revenue routes: platform subscriptions, national healthcare programmes, pharma partnerships and diagnostic licensing.
Interim results: revenue up 17%, losses narrowing, cash thin
For the six months to 31 March 2026, reported on 30 June 2026, revenue rose 17% to £0.69m (H1 FY25: £0.59m). Gross Margin slipped to 49.8% from 52.1%. Operating loss narrowed 20% to £4.68m and loss before tax fell 22% to £4.58m, helped by staff costs falling to £2.07m from £2.59m as average headcount dropped from 44 to 37. Loss per share was 0.1p against 0.7p, flattered by the far larger share count.
PSE orders were the standout: 1,788 in the half, up 126% on 791 a year earlier and 66% above the second half of FY25. CiRT orders fell because the PROWES study was paused. Cash was £2.51m at 31 March 2026 after the £7m November 2025 placing, but only £1.38m by 31 May 2026.
For the year to 30 September 2025, revenue was £1.1m (FY24: £0.6m), operating loss £11.1m (FY24: £12.9m) and loss before tax £11.4m, with year-end cash of £1.4m. The auditors' opinion carried an emphasis of matter on going concern, and the interims repeated the "material uncertainties" language. No Dividend is paid.
What could drive the stock next?
The first commercial Orion agreement, announced on 28 July 2026 with the UK government-funded OPTIMISE psoriatic arthritis programme led by the University of Oxford, was described by Compton as "the first time a partner has paid for access to Orion's capabilities". Terms were undisclosed, but the interims said Orion was in commercial discussions with three major pharma companies; a signed pharma deal would be a material step.
PSE distribution is broadening. MK Commercial was appointed on 30 June 2026 as a US contract sales partner, and on 13 August 2026 Dubai London Clinics & Hospitals became the first Gulf partner, with samples collected in the UAE and processed in the UK. Further catalysts include the placing-funded NHS PSE pilot, the ME/CFS test launch targeted for late 2026, colorectal cancer study data, an NCCN guidelines application for CiRT, and FY26 preliminary results due around December.
Risks investors should watch
Funding is the dominant risk. Oxford BioDynamics raised £7.35m in early 2025, £7m in November 2025 at 0.3p and £9.15m in August 2026 at 0.1p. The 12-month working capital statement relies on revenues from transactions not yet agreed, so another raise within a year cannot be ruled out. An operating loss of £11.1m in FY25 against revenue of £1.1m means the gap is structural, not marginal.
The sub-penny share price and 13.4bn shares in issue make the stock highly volatile and exposed to further dilution, including 260.85m two-year broker warrants exercisable at 0.2p. CiRT sales are constrained pending guideline inclusion, PSE growth depends on clinician adoption, and Orion is commercially unproven. The chief executive has been in post only since June 2026 and the nominated adviser changed in February 2026.
Outlook
Oxford BioDynamics (LSE:OBD) enters its 2027 financial year with a funded runway, a commercially minded chief executive and evidence that PSE Demand is compounding. The next twelve months will show whether Orion can win pharma subscriptions and whether PSE partnerships in the US, UAE and NHS generate revenue on a scale that changes the funding picture. Investors should track PSE order data, any disclosed Orion contract values, cash burn in the FY26 results and the pace at which the board delivers the "transactions that have not yet been agreed" on which its going-concern case rests.






Please wait processing your request...